Endovascular techniques have been used in our practice for more than 3 decades, although the increase in volume of procedures has accelerated during the last few years. The rationale for using these techniques is to lessen operative trauma to the patient by minimizing or eliminating the incision, reducing blood loss, and shortening or avoiding general anesthesia. These features in turn reduce or eliminate the need for postoperative intensive care and allow the patient to ambulate sooner, so that hospitalization is reduced.
Very few randomized trials have compared endovascular with open vascular surgery, and there is no level-1 evidence to support most of the endovascular techniques. Nonetheless, the use of endovascular procedures to treat occlusive and aneurysmal diseases has produced results equal to those that can be achieved with open vascular surgery in certain vascular beds. Here, we will focus on some of these regions: aortoiliac stenosis/occlusion, femoral lesions, renal artery stenosis, visceral artery stenotic/occlusive lesions, carotid artery lesions, and aortic aneurysms.
AORTOILIAC STENOSIS/OCCLUSION
Patients with occlusive disease in the aortoiliac region and claudication that does not respond to walking exercise or medical therapy may benefit from an intervention, which is most often offered as a means of improving the quality of life. The indication for aortoiliac angioplasty in our practice is a walking distance that disables the patient, usually ϳ200 meters. However, balloon angioplasty is seldom performed alone, as the results with adjunctive stenting are superior, 1 although this applies more to the central vessels than in the periphery (e.g., the femoropopliteal segment).
During the last 10 years, our use of open vascular surgery with aortobifemoral bypass grafting has dramatically decreased in favor of dilation/stenting for patients Ͼ70 years old. In 1993, the number of iliac stent procedures in Cologne was 87; in 2003, the number had increased to 150. For younger patients, however, the bifurcated graft is still our method of choice, especially when there are occlusions in the common and external iliac segments. In male patients, the use of angioplasty/stenting may retain sexual function, which might otherwise be jeopardized with a conventional surgical approach. Using this strategy, our number of aortobifemoral prosthetic implantations decreased from 82 in 1993 to 32 in 2003. Notably, the typical open surgery patient today has a more technically demanding anatomy because the ''easier'' cases are being treated with angioplasty/stenting. Perhaps this is why the results of open surgery have shown no improvement for many years.
Importantly, our total number of patients has risen over the past decade. Rather than resulting from a broadening of the indications for intervention, this increase in patient volume reflects our ability to treat patients who would have been deemed too high risk for open abdominal aortic surgery. For example, we can treat multilevel disease with an endovascular technique using one puncture and the crossover technique in many cases. In some patients, a prerequisite for a femoropopliteal reconstruction is the need to treat an iliac stenosis or occlusion to increase inflow to the groin. In such cases, it is advantageous if we can use the endoluminal technique either shortly before or during open surgery. Of course, a second explanation for our growing patient volume is the fact that more patients are being referred to our center for an endovascular procedure.
The use of endovascular techniques has also reduced the length of stay from Ͼ21 days for an aortobifemoral graft patient in 1993 to Ͻ3 days in 2003 for a patient undergoing angioplasty/stenting of aortoiliac disease. Both percutaneous balloon dilation with stenting and bifurcated graft implantation have similar 1-year patency rates of ϳ95% in this region.
FEMORAL LESIONS
Lesions of the common femoral artery, as well as stenoses at the takeoff of the profunda femoris artery, are still managed in the open fashion. These locations are easy to access by open surgery, and the risk of compression precludes the use of a stent at this location. The standard treatment in our center for lesions Ͼ10 cm is to bypass the diseased segment. Shorter stenotic or occluded segments are often balloon dilated then treated with 12-Gy gamma radiation according to a well described protocol. 2 We do not use drug-eluting stents as yet. Lengthy occluded segments are sometimes treated with a combination of thrombolysis (urokinase) followed by dilation of the unmasked short stenosis.
We have not used stents in the superficial femoral artery due to the poor results in that area 3 ; however, the data regarding nitinol stents is encouraging and may change our attitude. The use of graft-covered stents has achieved good outcomes in nonrandomized trials, with a 1-year primary patency rate of 78%. 4 We are currently participating in a prospective, randomized multicenter trial comparing the patency, cost, and quality of life achieved with a polytetrafluoroethylene (PTFE) graft-covered stent compared to PTFE bypass grafting.
We typically use an in situ saphenous vein technique to treat femoropopliteal lesions requiring a femoropopliteal or femorocrural bypass. Although we ligate all visible fistulas seen on the intraoperative angiogram, it is not uncommon that an arteriovenous fistula (AVF) will develop during the first postoperative week. In such cases, it is very convenient for the patient to undergo coil embolization of the fistulas, which is effective in Ͼ95% of the cases and has a very low complication rate.
In patients with only one superficial AVF, a small cutdown and open ligation are usually all that is required.
RENAL ARTERY STENOSIS
The indication for treatment of a renal artery stenosis in our practice is uncontrolled hypertension or the need for 3 or more drugs to control blood pressure. In patients with slight to moderate renal impairment, the motivation is to forestall further renal impairment and to prevent renal failure. Being aware of reports documenting the benefits of renal artery angioplasty/stenting in hypertensive patients, we feel that renal artery revascularization may be helpful to patients with a high-grade stenosis and no substantial loss of intraparenchymal arterioles. 5 In the last 10 years, renal artery revascularization has changed substantially. The use of stents has improved the patency rates, particularly in ostial lesions, and the number of procedures has increased from 10/year to almost 50/year. At the same time, surgical revascularization, which is now mostly performed in patients with occlusions or failure after angioplasty/stenting, has declined from 20 to 5 procedures annually. A small proportion of the patients undergo primary renal artery stenting prior to endovascular grafting for abdominal aortic aneurysm (AAA).
VISCERAL ARTERY STENOSIS
The need for visceral artery revascularization is not great, and the preinterventional (surgical or endovascular) workup is time-consuming and resource intensive. Because there are so few cases reported, the results cannot be compared in a meaningful way. The open procedure still bears a relatively high morbidity rate, 6 so we have shifted to angioplasty/stenting as the first-choice treatment for visceral artery ostial lesions. Our volume of endovascular procedures in these vessels has increased from 2/year in 1993 to 12 cases in 2003, while the number of open procedures has stayed the same, with only a few cases performed annually.
CAROTID ARTERY LESIONS
There is much debate about which method is the safest and most effective for the treatment of asymptomatic and symptomatic carotid artery lesions, but evidence-based proof supports the surgical technique in both symptomatic and asymptomatic high-grade stenosis. [7] [8] [9] Basically, our indications for carotid artery intervention are a high-grade stenosis Ͼ70% in symptomatic patients and Ͼ80% in asymptomatic patients with a life expectancy Ͼ3 years. In 1993, carotid endarterectomy in Cologne was exclusively done under general anaesthesia; the somatosensory evoked potential was routinely measured to predict the need for an intraoperative shunt. Since 2000, the use of local anaesthesia and the ''squeezing duck'' technique 10 have considerably simplified neurological monitoring during the procedure. A secondary benefit is that our rate of postoperative myocardial infarction has decreased significantly: only 1 patient in Ͼ500 cases suffered a clinically detected myocardial infarction within 30 days after the procedure.
The introduction of carotid artery stenting was begun years earlier for the same indications in patients with high-grade restenosis, hostile necks (following radiation or radical neck surgery), or inaccessible distal stenoses. In Cologne, carotid artery stenting has increased over the years from 2 cases in 1993 to 15 procedures in 2003. The combined stroke and mortality rates in our department are 1.8% after open surgery and 6% after stenting, which is usually performed without a protection device in our practice. Thus, our results compare well with those reported in the literature. 11 Endovascular treatment of proximal subclavian or brachiosubclavian stenosis is another area in which endoluminal techniques have gained popularity, not due to better or equal patency, 12 but because the patient is aware of the reduced trauma of the procedure. In occlusions, however, the success and patency rates are lower than experienced with repair of stenotic lesions.
ABDOMINAL AORTIC ANEURYSMS
According to Dias et al., 13 the broad application of endovascular AAA treatment without selection of only ''poor surgical risk'' patients could increase the mortality rates associated with open surgery. If, on the other hand, EVAR were performed primarily in patients judged to be poor risks for open surgery, one could expect a decrease in the 30-day mortality in the conventionally treated patient group. Stent-grafts for treating AAA were not available in Cologne until 1998, but there has been a steady increase thereafter, from 5 to 10 cases performed in the first few years to Ͼ40 cases in 2003. As the proportion of AAAs being treated with EVAR has increased from 10% to 25% at our center, there has been a concomitant rise in the total number of AAAs being treated, which is notable because our indication for surgery has become more restrictive (aneurysm diameter raised from 4 to 5 cm). Thus, there has been an increase in the total number of patients being referred to us for treatment of AAA.
Between 1993 and 1998, our 30-day mortality was 4.5% for conventionally treated AAA patients. In the last 5 years, the 30-day mortality for elective cases (nϭ407) has fallen to 1.5%: 1% in the open group (nϭ297) and 2.7% among the 110 patients receiving EVAR. Thus, in our center, there has been a reduction in mortality in the open repair group since the sicker patients are being treated with EVAR. Still, the deaths in this group have been few, and the overall mortality rate has decreased with the introduction of endovascular techniques. On the other hand, reinterventions after EVAR are more numerous than after open repair, 14 but most of them can be done endoluminally, with less trauma to the patient.
We have just begun an EVAR program for ruptured AAA, and our initial experience is positive, although there are too few cases to J ENDOVASC THER 2004;11 (Suppl II):II-5-II-9 make a realistic comparison with the open repair, which still has a 45% mortality rate at our institution.
THORACIC AORTIC ANEURYSMS
The most dramatic effect seen from the patient's perspective, though, is the introduction of endovascular techniques for the treatment of thoracic aortic diseases. We began treating thoracic lesions in 1999 at Cologne University Clinics; initially, there were a couple of cases a year, but this number has steadily grown to about 10 to 15 cases a year. The indications for treatment are elective true aneurysms and acute ruptures of true as well as traumatic aneurysms.
In patients with acute dissections, invasive treatment has been carried out selectively when there has been bleeding, persistent pain, medication-resistant hypertension, or malperfusion of the visceral, renal, or lower limb arteries. Prior to the introduction of endovascular techniques, open surgery was required, with its well-known morbidity (e.g., renal failure, pulmonary dysfunction, and heart failure). After we began using minimally invasive techniques, such as endovascular fenestration for lower limb malperfusion, stenting of a compressed true lumen, and recanalization/stenting of the renal or visceral arteries, morbidity has decreased significantly. The new concept of covering the entry tear with a stent-graft 15 in patients with dissections but without any complications has so far not been widely used in our practice.
The application of stent-grafts in acute cases has certainly altered the treatment for patients with ruptured aneurysms, particularly those who would not be candidates for open surgery. Some two thirds of patients with thoracic aortic ruptures referred to us for stentgraft repair would have been denied open treatment. The mortality was 2 of 20 patients, which is in line with data presented in the literature. 16 The paraplegia rate in our group was luckily zero, which is comparable to literature reports as well. 16 The intensive care of patients with rupture of the thoracic aorta, which could have been weeks for conventionally treated patients, has been cut to 2 to 3 days if no concomitant disease is present. En-dovascular techniques have thus made it possible for us to treat more patients less traumatically and with more benefits to the patient. More patients have been referred to us for this treatment, which, in our belief, has had a positive effect on the community.
In conclusion, the introduction of endovascular techniques has dramatically changed the vascular surgeon's armamentarium for treating vascular diseases. The overall morbidity and mortality has declined for patients with aneurysm in the abdominal as well as the thoracic aorta. The use of endovascular stents for aortoiliac occlusive disease has also decreased morbidity and improved quality of life. Carotid artery stenting has not led to any decrease in stroke or mortality, but we have treated more patients who otherwise would have received only medical therapy. Our practice volume overall has increased due to broader applicability of these minimally invasive techniques without the need to increase staff or equipment, with the exception of stent-grafts.
